Announced Sat, 18 Jul · 19:02 IST
AstraZeneca Pharma India files BRSR for FY 2025-26 with KPMG limited assurance
Compliance View source PDF
ASTRAZEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+0.6%1-day move
₹8022.50
prior close
—
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————+0.6-0.1-1.8-0.1+1.1—————
Up moveDown movePending
AI summary
AstraZeneca Pharma India submitted its Business Responsibility and Sustainability Report for FY 2025-26 with limited assurance from KPMG. Standalone turnover was Rs 22,755.8 million and net worth Rs 8,727.9 million. Exports contributed 5.2 percent. The company has 760 permanent employees and no workers as factory operations were ceased during the year. No fines, penalties, or corruption cases were reported.
Likely market impact
Routine SEBI compliance filing. Highlights ESG progress, factory closure impact, governance, and diversity with women on 83 percent of board seats.